Search

Displaying results 401 - 410 of 2517 in total
  1. Drug

    PD-0299685

    go.drugbank.com/drugs/DB15264
    Investigational

    PD-0299685 is under investigation in clinical trial NCT00314964 (Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause).

  2. Drug

    PF-04620110

    go.drugbank.com/drugs/DB14887
    Investigational

    PF-04620110 is under investigation in clinical trial NCT01146327 (A Multiple Dose Study Of PF-04620110 In Healthy Overweight Or Obese Subjects).

  3. Target

    Volume-regulated anion channel subunit LRRC8A

    go.drugbank.com/bio_entities/BE0016599
    TargetHumans

    Essential component of the volume-regulated anion channel (VRAC, also named VSOAC channel), an anion channel required to maintain a constant cell volume in response to extracellular or intracellular osmotic changes (PubMed:24725410, PubM...

    Synonyms: Leucine-rich repeat-containing protein 8A
  4. Drug

    PF-04634817

    go.drugbank.com/drugs/DB14955
    Investigational

    PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).

  5. Drug

    PF-07038124

    go.drugbank.com/drugs/DB19143
    Investigational

    PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

  6. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

    Synonyms: PD-L1/4-1BB bispecific antibody
  7. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment.

  8. Drug

    Gotistobart

    go.drugbank.com/drugs/DB19100
    Investigational

    Gotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).

  9. Target

    Transforming growth factor beta activator LRRC32

    go.drugbank.com/bio_entities/BE0014554
    TargetHumans

    Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space (PubMed:19651619, PubMed:19750484, PubMed:22278742). As...

    Synonyms: Leucine-rich repeat-containing protein 32
  10. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: PR Natal 430, PR Natal 400